SCHEMBL4297119

SCHEMBL4297119

COC(=O)c1cc2ccncc2c2cc(Cl)c(C(Br)Br)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 2/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
HTT P42858 1/20 0.39
PIM1 P11309 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
NR4A2 P43354 3/20 0.37
CSNK2A2 P19784 1/20 0.37
CSNK2B P67870 1/20 0.37
AXL P30530 1/20 0.37
CSNK2A1 P68400 2/20 0.36
PARP1 P09874 1/20 0.36
TGFBR1 P36897 1/20 0.35
MAP2K1 Q02750 1/20 0.34
HPGD P15428 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ROCK2 O75116 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4290175 0.83 KDM4E (0.43) KDM4EALDH1A1GLAGAAHTT
SCHEMBL4292026 0.81 KDM4E (0.42) KDM4EALDH1A1GLAGAAHTT
SCHEMBL4296278 0.81 KDM4E (0.40) KDM4EALDH1A1GLAGAAHTT
SCHEMBL4300956 0.78 CHEK1 (0.53) KDM4EALDH1A1GLAGAAHTT
SCHEMBL4288029 0.76 CHEK1 (0.53) KDM4EALDH1A1GLAGAAHTT
SCHEMBL13659554 0.75 KDM4E (0.67) KDM4EALDH1A1GLAGAAHTT
SCHEMBL26703728 0.72 KDM4E (0.54) KDM4EALDH1A1GLAGAAHTT
SCHEMBL23043865 0.68 KDM4E (0.57) KDM4EALDH1A1GLAGAAAXL
SCHEMBL29760386 0.68 KDM4E (0.57) KDM4EALDH1A1GLAGAAAXL
SCHEMBL29707053 0.68 KDM4E (0.57) KDM4EALDH1A1GLAGAAAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
EP-1904449-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2008-04-02 EP disclosed
WO-2007008502-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-01-18 WO disclosed
WO-2007008502-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258852-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, CDKN1A KDM4E 366/4885ALDH1A1 2405/4885GLA 3572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.